XML 35 R6.htm IDEA: XBRL DOCUMENT v3.23.4
Statements of Cash Flows
 12 Months Ended
Dec. 31, 2021
USD ($)
Cash flows from operating activities:  
Net loss $ (6,843,399)
Adjustments to reconcile net loss to net cash used in operating activities  
Depreciation 42,470
Share-based compensation expense 185,996
Loss on sale of equipment 3,082
Change in fair market value of derivative liabilities 867,000
Non-cash interest expense 39,471
Change in fair value of warrant liability (see statements of operations) 6,109
Changes in assets and liabilities:  
Prepaid expenses and other current assets (1,903,114)
Accounts payable and accrued expenses 2,285,059
Deferred grant income 30,528
Payment of amount due to related parties (35,685)
Accrued interest on convertible promissory notes 55,598
Net cash used in operating activities (5,266,885)
Cash flows from investing activities:  
Purchase of equipment (254,820)
Proceeds from sale of equipment 3,000
Net cash used in investing activities (251,820)
Cash flows from financing activities:  
Proceeds from initial public offering (IPO) of common stock, net of offering costs 26,335,100
Proceeds from subscription receivable 13,125
Proceeds from exercise of warrants 29,267
Payments of deferred offering costs (860,943)
Net cash provided by (used in) financing activities 25,516,549
Net change in cash 19,997,844
Cash, beginning of period 828,016
Cash, end of period 20,825,860
Supplemental disclosure of cash flow  
Interest 17,870
Supplemental disclosure of non-cash investing and financing activities:  
Accrued interest on subscriptions receivable 362
Conversion of convertible promissory notes, including embedded derivative, to common stock 4,991,431
Deferred offering costs adjusted into additional paid-in capital in connection with IPO 73,484
Fair value of warrant liability associated with warrant exercise 35,485
Underwriting discounts and commissions paid from gross proceeds of IPO $ 2,414,900